Salmeterol, a β2-receptor agonist, attenuates lipopolysaccharide-induced lung inflammation in mice

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 286, Issue 6 30-6, 2004, Pages

  Maris, Nico A ^a   Van Der Sluijs, Koenraad F ^a   Florquin, Sandrine ^a   De Vos, Alex F ^a   Pater, Jennie M ^a   Jansen, Henk M ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Bronchodilator agents; Endotoxins; Neutrophils

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CD11B ANTIGEN; LIPOPOLYSACCHARIDE; SALMETEROL; BETA 2 ADRENERGIC RECEPTOR; BRONCHODILATING AGENT; DRUG DERIVATIVE; SALBUTAMOL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; ATTENUATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; LUNG LAVAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SURFACE PROPERTY; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG POTENTIATION; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG ALVEOLUS; METABOLISM; NEUTROPHIL;

ADMINISTRATION, INHALATION; ALBUTEROL; ANIMALS; ANTIGENS, CD11B; BRONCHODILATOR AGENTS; CHEMOTAXIS, LEUKOCYTE; FEMALE; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NEUTROPHILS; PNEUMONIA; PULMONARY ALVEOLI; RECEPTORS, ADRENERGIC, BETA-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2942624425     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00125.2003     Document Type: Article

References (46)

1. Abraham E, Kaneko DJ, and Shenkar R. Effects of endogenous and exogenous catecholamines on LPS-induced neutrophil trafficking and activation. Am J Physiol Lung Cell Mol Physiol 276: L1-L8, 1999.
2. Baker AJ, Palmer J, Johnson M, and Fuller RW. Inhibitory actions of salmeterol on human airway macrophages and blood monocytes. Eur J Pharmacol 264: 301-306, 1994.
3. Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, Johnson M, Lunts LH, Nials AT, Sheldrick KE, and Skidmore IF. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 104: 665-671, 1991.
4. Barnes PJ. Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 104: S10-S17, 1999.
5. Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 152: 838-860, 1995.
6. Bentwood BJ and Henson PM. The sequential release of granule constitutents from human neutrophils. J Immunol 124: 855-862, 1980.
7. Burg ND and Pillinger MH. The neutrophil: function and regulation in innate and humoral immunity. Clin Immunol 99: 7-17, 2001.
8. Calhoun WJ, Stevens CA, and Lambert SB. Modulation of superoxide production of alveolar macrophages and peripheral blood mononuclear cells by beta-agonists and theophylline. J Lab Clin Med 117: 514-522, 1991.
9. Chong LK, Cooper E, Vardey CJ, and Peachell PT. Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms. Br J Pharmacol 123: 1009-1015, 1998.
10. Clark RB, Allal C, Friedman J, Johnson M, and Barber R. Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. Mol Pharmacol 49: 182-189, 1996.
11. Derian CK, Santulli RJ, Rao PE, Solomon HF, and Barrett JA. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J Immunol 154: 308-317, 1995.
12. Doerschuk CM, Tasaka S, and Wang Q. CD11/CD18-dependent and -independent neutrophil emigration in the lungs: how do neutrophils know which route to take? Am J Respir Cell Mol Biol 23: 133-136, 2000.
13. Ezeamuzie CI and al-Hage M. Differential effects of salbutamol and salmeterol on human eosinophil responses. J Pharmacol Exp Ther 284: 25-31, 1998.
14. Goncalves de Moraes VL, Boris Vargaftig B, Lefort J, Meager A, and Chignard M. Effect of cyclo-oxygenase inhibitors and modulators of cyclic AMP formation on lipopolysaccharide-induced neutrophil infiltration in mouse lung. Br J Pharmacol 117: 1792-1796, 1996.
15. Goncalves de Moraes VL, Singer M, Vargaftig BB, and Chignard M. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Br J Pharmacol 123: 631-636, 1998.
16. Green SA, Spasoff AP, Coleman RA, Johnson M, and Liggett SB. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 271: 24029-24035, 1996.
17. Hirano S. Quantitative time-course profiles of bronchoalveolar lavage cells following intratracheal instillation of lipopolysaccharide in mice. Ind Health 35: 353-358, 1997.
18. Izeboud CA, Mocking JA, Monshouwer M, van Miert AS, and Witkamp RF. Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release. J Recept Signal Transduct Res 19: 191-202, 1999.
19. Johnson M. Beta-2-agonists as anti-inflammatory therapies in the lung. Agents Actions 41: 27-45, 1993.
20. Johnson M and Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest 120: 258-270, 2001.
21. Kavelaars A, van de Pol M, Zijlstra J, and Heijnen CJ. Beta 2-adrenergic activation enhances interleukin-8 production by human monocytes. J Neuroimmunol 77: 211-216, 1997.
22. Leemans JC, Vervoordeldonk MJ, Florquin S, Van Kessel KP, and Van Der Poll T. Differential role of interleukin-6 in lung inflammation induced by lipoteichoic acid and peptidoglycan from Staphylococcus aureus. Am J Respir Crit Care Med 165: 1445-1450, 2002.
23. Maisel AS, Fowler P, Rearden A, Motulsky HJ, and Michel MC. A new method for isolation of human lymphocyte subsets reveals differential regulation of beta-adrenergic receptors by terbutaline treatment. Clin Pharmacol Ther 46: 429-439, 1989.
24. Moreland JG, Fuhrman RM, Wohlford-Lenane CL, Quinn TJ, Benda E, Pruessner JA, and Schwartz DA. TNF-alpha and IL-1 beta are not essential to the inflammatory response in LPS-induced airway disease. Am J Physiol Lung Cell Mol Physiol 280: L173-L180, 2001.
25. Nials AT, Coleman RA, Johnson M, and Vardey CJ. The duration of action of non-beta 2-adrenoceptor mediated responses to salmeterol. Br J Pharmacol 120: 961-967, 1997.
26. Olson TS and Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 283: R7-R28, 2002.
27. Ottonello L, Morone P, Dapino P, and Dallegri F. Inhibitory effect of salmeterol on the respiratory burst of adherent human neutrophils. Clin Exp Immunol 106: 97-102, 1996.
28. Rijneveld AW, Lauw FN, Schultz MJ, Florquin S, Te Velde AA, Speelman P, Van Deventer SJ, and Van Der Poll T. The role of interferon-gamma in murine pneumococcal pneumonia. J Infect Dis 185: 91-97, 2002.
29. Saleh TS, Calixto JB, and Medeiros YS. Anti-inflammatory effects of theophylline, cromolyn and salbutamol in a murine model of pleurisy. Br J Pharmacol 118: 811-819, 1996.
30. Schmal H, Shanley TP, Jones ML, Friedl HP, and Ward PA. Role for macrophage inflammatory protein-2 in lipopolysaccharide-induced lung injury in rats. J Immunol 156: 1963-1972, 1996.
31. Seebeck J, Krebs D, and Ziegler A. Influence of salmeterol and benzalkonium chloride on G-protein-mediated exocytotic: responses of rat peritoneal mast cells. Eur J Pharmacol 397: 19-24, 2000.
32. Sekut L, Champion BR, Page K, Menius JA Jr, and Connolly KM. Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin Exp Immunol 99: 461-466, 1995.
33. Severn A, Rapson NT, Hunter CA, and Liew FY. Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic: agonists. J Immunol 148: 3441-3445, 1992.
34. Skerrett SJ, Martin TR, Chi EY, Peschon JJ, Mohler KM, and Wilson CB. Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 276: L715-L727, 1999.
35. Strieter RM, Belperio JA, and Keane MP. Cytokines in innate host defense in the lung. J Clin Invest 109: 699-705, 2002.
36. Suberville S, Bellocq A, Fouqueray B, Philippe C, Lantz O, Perez J, and Baud L. Regulation of interleukin-10 production by beta-adrenergic agonists. Eur J Immunol 26: 2601-2605, 1996.
37. Svedmyr N. The current place of beta 2-agonists in the management of asthma. Lung 168 Suppl: 105-110, 1990.
38. Szabo C, Hasko G, Zingarelli B, Nemeth ZH, Salzman AL, Kvetan V, Pastores SM, and Vizi ES. Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia. Immunology 90: 95-100, 1997.
39. Szarka RJ, Wang N, Gordon L, Nation PN, and Smith RH. A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation. J Immunol Methods 202: 49-57, 1997.
40. Tsai WC, Strieter RM, Mehrad B, Newstead MW, Zeng X, and Standiford TJ. CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect Immun 68: 4289-4296, 2000.
41. Tsai WC, Strieter RM, Wilkowski JM, Bucknell KA, Burdick MD, Lira SA, and Standiford TJ. Lung-specific transgenic expression of KC enhances resistance to Klebsiella pneumoniae in mice. J Immunol 161: 2435-2440, 1998.
42. Van der Poll T, Coyle SM, Barbosa K, Braxton CC, and Lowry SF. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during. J Clin Invest 97: 713-719, 1996.
43. Van der Poll T and Lowry SF. Lipopolysaccharide-induced interleukin 8 production by human whole blood is enhanced by epinephrine and inhibited by hydrocortisone. Infect Immun 65: 2378-2381, 1997.
44. Wagner JG and Roth RA. Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacol Rev 52: 349-374, 2000.
45. Whelan CJ, Johnson M, and Vardey CJ. Comparison of the antiinflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. Br J Pharmacol 110: 613-618, 1993.
46. Wu CC, Liao MH, Chen SJ, Chou TC, Chen A, and Yen MH. Terbutaline prevents circulatory failure and mitigates mortality in rodents with endotoxemia. Shock 14: 60-67, 2000.